SARS-CoV-2 PLpro-IN-3

SARS-CoV-2 PLpro-IN-3 (Compound 15) is a covalent inhibitor of the SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 25 nM. SARS-CoV-2 PLpro-IN-3 has similar inhibitory activity against SARS-CoV PLpro (IC50 = 59 nM), but shows no inhibitory effect on human ubiquitin-specific protease 7 (USP7) . The EC50 of SARS-CoV-2 PLpro-IN-3 in inhibiting SARS-CoV-2 replication in cells is 96 nM, significantly reducing the viral titer and viral RNA levels. SARS-CoV-2 PLpro-IN-3 can be used for studying SARS-CoV-2 drug resistance mutations[1].

Product Specifications

UNSPSC

12352005

Target

SARS-CoV; Virus Protease

Related Pathways

Anti-infection

Field of Research

Infection

Smiles

O=C(N[C@@H](C1=C2C=CC=CC2=CC=C1)C)C3=CC=CC=C3CCC(NNC(/C=C/C(NC4=CC=CN=C4)=O)=O)=O

Molecular Formula

C31H29N5O4

Molecular Weight

535.59

References & Citations

[1]Garad DN, et al. Targeting the S1' Pocket of SARS-CoV‑2 Papain-Like Protease Yields Highly Potent Inhibitors. ACS Med Chem Lett. 2025 Oct 30;16 (11) :2280-2285.